What is IXC Management doing well ?, page-25

Tom is a rare beast in our listed small cap pharma ecosystem and we are all the better for it, I am also a fan of Jon Pilcher at Neuren. Both understand what it means to be a LISTED clinical pharma and the peculiarities entailed with that.

What they get and others struggle with, is that investors can forgive clinical failure, provided it was based on a reasonable hypothesis, it was not hyped, IR was consistent and to the extent possible timely, that investors were treated fairly with respect to CR's and issues of corporate governance, and that the board understood the necessity to being sufficiently funded to the next milestone. Both of these gentlemen associate themselves with quality, once you have rolled around in the mud it is almost impossible to remove and there is a lost of mud out there.

Good for Tom and good for pharma investors....